Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
DiaMedica Therapeutics Inc
NASDAQ DMAC
Data sourced from
and
and
DiaMedica Therapeutics Inc Debt to Tangible Net Worth Ratio 3 year CAGR for the quarter ending June 30, 2019
DiaMedica Therapeutics Inc Debt to Tangible Net Worth Ratio 3 year CAGR is NA for the quarter ending June 30, 2019. The debt to tangible net worth ratio measures the level of debt relative to a company's tangible net worth. It is calculated by dividing total debt by the difference between shareholders' equity and intangible assets (such as goodwill). This ratio provides insights into the company's financial leverage, excluding intangible assets. A higher ratio suggests a higher level of debt burden in relation to tangible net worth. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: DMAC
| CEO | Mr. Dietrich John Pauls MBA |
| IPO Date | Jan. 4, 2008 |
| Location | United States |
| Headquarters | Two Carlson Parkway, Minneapolis, MN, United States, 55447 |
| Employees | 18 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Key trends
Similar companies
Milestone Pharmaceuticals Inc
NA
NA
Centessa Pharmaceuticals PLC ADR
NA
NA
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email